Granted Patent B2

US 8,420,079 · App. 13/223,373 · Granted Apr 16, 2013

Abstract

Claims (23)

1. A polypeptide comprising a single N-terminal kringle domain which is at least 90% identical to the kringle 1 domain of native human plasminogen; and directly and covalently attached to a C-terminal domain which is at least 90% identical to the activation site and serine protease domain of native human plasminogen; wherein the polypeptide binds to immobilized lysine and can be activated by a plasminogen activator.

2. The polypeptide of claim 1 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2 with no more than 30 amino acid substitutions.

3. The polypeptide of claim 1 , wherein the polypeptide exhibits a fibrinolytic activity that is inhibited by α2-antiplasmin at a rate of inhibition that is at least about 5-fold faster than the rate of inhibition of the fibrinolytic activity of mini-plasmin by α2-antiplasmin.

4. The polypeptide of claim 3 , wherein the rate of inhibition is at least 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin.

5. The polypeptide of claim 1 , wherein the immobilized lysine is lysine bound to a solid support matrix selected from the group consisting of lysine-agarose, lysine-hydrogel, and lysine-cross-linked agarose.

6. The polypeptide of claim 5 , wherein the immobilized lysine is lysine-cross-linked agarose.

7. The polypeptide of claim 1 , wherein the polypeptide exhibits a lower binding affinity for fibrinogen than the binding affinity for fibrinogen of mini-plasmin.

8. The polypeptide of claim 1 , wherein the polypeptide exhibits higher binding affinity for partially cleaved fibrin than the binding affinity for partially cleaved fibrin of mini-plasmin.

9. A pharmaceutical composition comprising:

the polypeptide of claim 1 which has been cleaved at its activation site by a plasminogen activator and purified; and

a low pH-buffering capacity agent;

wherein the polypeptide in said pharmaceutical composition is acidified and reversibly inactive.

10. The pharmaceutical composition of claim 9 , wherein the polypeptide is within a concentration range of about 0.1 mg/mL to about 10 mg/mL.

11. The pharmaceutical composition of claim 9 , wherein the composition has a pH between about 2.5 to about 4.0.

12. The pharmaceutical composition of claim 9 , wherein the low pH-buffering capacity agent is acetic acid, citric acid, hydrochloric acid, lactic acid, malic acid, tartaric acid, benzoic acid, serine, threonine, methionine, glutamine, alanine, glycine, isoleucine, valine, aspartic acid, derivatives thereof, or combinations thereof.

13. The pharmaceutical composition of claim 11 , wherein the low pH-buffering capacity agent is citric acid.

14. The pharmaceutical composition of claim 9 , further comprising a stabilizing agent.

15. The pharmaceutical composition of claim 14 , wherein the stabilizing agent is a sugar or sugar alcohol selected from glucose, maltose, mannitol, sorbitol, sucrose, lactose, trehalose, or combinations thereof.

16. The pharmaceutical composition of claim 15 , wherein the stabilizing agent is trehalose.

17. The pharmaceutical composition of claim 14 , wherein the concentration of the stabilizing agent is in the range of about 0.01 M to about 1.0 M.

18. The pharmaceutical composition of claim 9 , wherein the composition is lyophilized.

19. The pharmaceutical composition of claim 9 , wherein the low pH-buffering capacity agent is present at a concentration at which the pH of the composition can be raised to a neutral pH by adding about an equal volume of serum to the composition.

20. The pharmaceutical composition of claim 9 , wherein the composition is a sterile solution having a pH between about 2.5 and about 4.0, that is suitable for administration without prior neutralization, and can be raised to physiological pH by adding no more than 5 volumes of serum to the solution relative to a volume of the solution.

Assignments (27)